Butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Closely. Coadministration of CYP3A4 inducers may reduce sufentanil ranges and efficacy, perhaps precipitating withdrawal syndrome in clients who may have developed Actual physical dependence to sufentanil. Discontinuation of concomitantly utilized CYP3A4 indu... https://howardu594ryf6.bloggosite.com/profile